Our Market Access Strategy unit recently held a workshop focused on Joint Clinical Assessment (JCA) learnings.
The session brought together perspectives from Quantify Research and our sister companies within the athagoras Group creating a valuable opportunity to learn from practical experience in JCA dossier preparation and strategy.
Together, we explored:
📌key considerations in preparing a JCA dossier
📌 how evidence planning connects to access strategy
📌 learnings from IGES Pharma hands-on experience
📌 collaboration areas across the athagoras group
As JCA becomes an increasingly important part of the European access landscape, clients need partners who understand both the technical dossier requirements and the strategic decisions behind them.
Across the athagoras Group, we have the experience to support clients through the JCA process, from early preparation to strategic alignment.
A valuable session, and a good reminder that robust access strategy is rarely built in isolation.
What part of JCA preparation do you think benefits most from cross-company collaboration?
